| Primary | Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza Tests | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had a PCR-confirmed positive influenza test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Number | | participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| | | Title | Denominators | Categories |
|---|
| | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| | Regression, Cox | Models were adjusted for age, age squared, sex, and race or ethnic group after weighting with stabilized facility-specific propensity scores. | <0.05 | Adjustment for multiplicity for the secondary outcomes was performed with the use of Holm's adjustment method. | Hazard Ratio (HR) | 0.85 | | | 2-Sided | 95 | 0.76 | 0.94 | | | Relative vaccine effectiveness (95% CI) calculated as 1 minus the hazard ratio, expressed as a percentage: 15.3% (5.9%, 23.8%) | | Other | |
|
| Secondary | Number of Adults 50-64 Years Old Hospitalized With PCR-confirmed Influenza | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay and had a PCR-confirmed positive influenza test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Number | | participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Secondary | Number of Adults 50-64 Years Old Hospitalized With Community-acquired Pneumonia | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay for community-acquired pneumonia (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Secondary | Number of Adults 50-64 Years Old Hospitalized With Cardio-respiratory Events | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay for cardio-respiratory events (e.g., pneumonia, other lower respiratory infections, acute myocardial infarction, congestive heart failure, stroke) (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
|
| Other Pre-specified | Number of Adults 18-49 Years Old Hospitalized With Community-acquired Pneumonia | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay for community-acquired pneumonia (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 50-64 Years Old With Influenza-Like Illness (ILI) | Patients who receive either Flublok or SD-IIV will be retroactively assessed (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30) for influenza-like illness (ILI) International Classification of Diseases, 10th Edition (and absence of a negative lab-confirmed influenza) | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 50-64 Years Old With All-Cause-Hospitalizations | Patients who receive either Flublok or SD-IIV will be retroactively assessed (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30) for all-cause hospitalizations | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 50-64 Years Old With All-Cause Mortality | Patients who receive either Flublok or SD-IIV will be retroactively assessed (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30) for all-cause mortality | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza Tests | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had a PCR-confirmed positive influenza test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Number | | participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 18-49 Years Old Hospitalized With PCR-confirmed Influenza | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay and had a PCR-confirmed positive influenza test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Number | | participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 18-49 Years Old Hospitalized With Cardio-respiratory Events | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay for cardio-respiratory events (e.g., pneumonia, other lower respiratory infections, acute myocardial infarction, congestive heart failure, stroke) (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
|
| Other Pre-specified | Number of Adults 18-49 Years Old With Influenza-Like Illness (ILI) | Patients who receive either Flublok or SD-IIV will be retroactively assessed (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30) for influenza-like illness (ILI) International Classification of Diseases, 10th Edition (and absence of a negative lab-confirmed influenza) | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 18-49 Years Old With All-Cause-Hospitalizations | Patients who receive either Flublok or SD-IIV will be retroactively assessed (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30) for all-cause hospitalizations | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 18-49 Years Old With All-Cause Mortality | Patients who receive either Flublok or SD-IIV will be retroactively assessed (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30) for all-cause mortality | | Posted | | Count of Participants | | Participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza A Tests | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had a PCR-confirmed positive influenza A test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Number | | participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Other Pre-specified | Number of Adults 18-49 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza B Tests | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had a PCR-confirmed positive influenza B test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Number | | participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Secondary | Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza A Tests | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had a PCR-confirmed positive influenza A test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Number | | participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |
| Secondary | Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza B Tests | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had a PCR-confirmed positive influenza B test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | | Posted | | Number | | participants | | Up to 8 months | | | | ID | Title | Description |
|---|
| OG000 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine. Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | | OG001 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV). Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. |
| |